AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...

Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint ...

According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

This month’s executive moves span a diverse range of organisations – from CDMOs and genomics platforms to diagnostics and ...

Back in May, health data company Datavant announced its plans to acquire Aetion, creating a formidable player in the ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

On day three of BIO 2025, editor-in-chief Jonah Comstock caught up with OS Therapies CEO Paul Romness and EVERSANA VP of ...

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from ...

US Health and Human Services (HHS) Secretary Robert F Kennedy Jr has formally signed off on a recommendation to remove ...

The 3rd Spatial Biology for Drug Development Summit is your opportunity to come together with leading biopharma experts to ...

SCOPE is testing administration of intramuscular SCIB1 and intradermal iSCIB1+, which codes for various melanoma antigens ...

This pricing shock immediately exposed pharma’s second crisis: R&D costs that continue to climb, now between $0.8 and $2.8 ...